DEC 28, 2020 6:00 AM PST

Inhaling a Puff of Llama Antibodies to Relieve COVID

WRITTEN BY: Tara Fernandez

Scientists at the National Institutes of Health have identified new antibody-based weapons in the fight against COVID-19 from an unlikely source—a llama named Cormac. Promisingly, these novel antibodies have the potential to be developed into inhalable therapeutic aerosols for treating COVID.

Camelids, an umbrella term for alpacas, camels, and llamas, produce two distinct forms of antibodies in response to invading pathogens such as viruses. While one resembles the Y-shaped protein structures of human antibodies, the other form is much smaller and unique to camelids—tiny antibodies known as “nanobodies”. These single-domain antibodies are of particular interest to drug developers for their ability to be converted into a fine mist for administration by inhalation. For respiratory infections like COVID-19, this means delivering these virus-neutralizing proteins as aerosols directly to the site of the infection.

Nanobodies are also more stable and cost-effective for producing in large quantities. 

Thomas J. "T.J." Esparza, B.S., and David L. Brody, M.D., Ph.D., from the NIH's National Institute of Neurological Disorders and Stroke (NINDS) led the discovery of NIH-CoVnb-112, the nanobody targeting SARS-CoV-2’s spike protein.

"For years TJ and I had been testing out how to use nanobodies to improve brain imaging. When the pandemic broke, we thought this was a once in a lifetime, all-hands-on-deck situation and joined the fight," said Brody

"We hope that these anti-COVID-19 nanobodies may be highly effective and versatile in combating the coronavirus pandemic."

In the hunt for COVID-19 therapeutics, several drug development groups have leveraged nanobody-based therapies' power and potential. However, Esparza and the team took a slightly different approach to find the needles in the haystack—nanobodies with particularly high affinities for the spike protein.

"The SARS-CoV-2 spike protein acts like a key. It does this by opening the door to infections when it binds to a protein called the angiotensin converting enzyme 2 (ACE2) receptor, found on the surface of some cells," said Esparza

"We developed a method that would isolate nanobodies that block infections by covering the teeth of the spike protein that bind to and unlock the ACE2 receptor."

Cormac the llama received five immunizations with the spike protein over the course of a month to trigger an immune response. Analysis of hundreds of nanobodies produced by Cormac’s immune system revealed around 13 lead candidates. NIH-CoVnb-112, in particular, stood out with its ability to bind to the ACE2 receptor up to 10 times tighter than other nanobody frontrunners, blocking the virus from entering host cells. 

Importantly, NIH-CoVnb-112 was able to be converted into an aerosol for administration to patients via an inhaler, similar to that used to dispense treatments for asthmatics. "One of the exciting things about nanobodies is that, unlike most regular antibodies, they can be aerosolized and inhaled to coat the lungs and airways," commented Brody.

According to Esparza, the data presented in the study represent a promising first step towards the commercialization of this therapeutic. "With support from the NIH, we are quickly moving forward to test whether these nanobodies could be safe and effective preventative treatments for COVID-19. Collaborators are also working to find out whether they could be used for inexpensive and accurate testing."

 

 

Sources: Scientific Reports, NIH.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 20, 2021
Immunology
Coronavirus Variants No Match Against Newly-Discovered Antibody
JUL 20, 2021
Coronavirus Variants No Match Against Newly-Discovered Antibody
Over 940 million people around the world have been fully vaccinated. But, as the World Health Organization warns, t ...
JUL 26, 2021
Cell & Molecular Biology
Cells Have a Self-Defense Mechanism Against Bacteria
JUL 26, 2021
Cells Have a Self-Defense Mechanism Against Bacteria
There are natural detergents that cells can use to defend themselves from pathogens. Scientists have now identified a pr ...
SEP 09, 2021
Cancer
Can a Mole Fight Melanoma?
SEP 09, 2021
Can a Mole Fight Melanoma?
About 30% of melanoma cases arise from an existing nevus.  More commonly known as moles, Nevi are skin growths that ...
SEP 03, 2021
Cell & Molecular Biology
Is a Venom-Like Molecule Involved in COVID-19 Mortality?
SEP 03, 2021
Is a Venom-Like Molecule Involved in COVID-19 Mortality?
Scientists have sought to learn more about why some people get severe COVID-19 while others have only mild cases. We kno ...
SEP 16, 2021
Immunology
Trapped! An Immune Cell Tag Team Takes Down Bacteria.
SEP 16, 2021
Trapped! An Immune Cell Tag Team Takes Down Bacteria.
Spiders are among nature’s most sophisticated hunters. Many build intricate webs out of silk and lie in wait for a ...
OCT 14, 2021
Immunology
'Bio-Betters' Form the Next Wave of Cancer Therapies
OCT 14, 2021
'Bio-Betters' Form the Next Wave of Cancer Therapies
  Antibodies are blood proteins with highly specialized functions: to recognize and eliminate bacteria, viruses, an ...
Loading Comments...